We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


DiscoveRx Launches Beta-Arrestin Assay Platform for High Throughput GPCR Screening

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

DiscoveRx Corporation has announced the launch of their PathHunter™ Beta-Arrestin assay, a universal G-protein coupled receptor screening platform that utilizes a proprietary ProLink™ tag along with the well established enzyme fragment complementation (EFC) technology.

Commenting on the launch Dr. Pyare Khanna, CEO of DiscoveRx said, "The PathHunter Beta-Arrestin assay is another revolutionary offering from DiscoveRx which further confirms our commitment to provide novel, chemiluminescent assays for both biochemical and cell based drug discovery research and screening."

"This product was developed in response to a market demand for a non-imaging, HTS technology for studying virtually any GPCR."

"With a product portfolio that includes Beta-Arrestin technology, HitHunter™ cAMP assays, HitHunter IP3 assays, Calcium NW and Coelenterazine reagents, DiscoveRx is the only GPCR assay provider that offers best-in-class screening solutions for every major type of GPCR target."

The PathHunter cell based assay platform utilizing the ProLabel™ tag has proven to be an enabling system for drug discovery that is dsigned to provide a unique assay platform to measure protein expression, degradation, secretion and translocation for a variety of drug discovery target classes.

With the launch of the ProLink tag and Beta-Arrestin Assay, a suite of PathHunter assays that revolve around protein-protein interactions will soon be possible.

DiscoveRx plans to offer the PathHunter Beta-Arrestin technology without need of any licensing arrangements.

The product portfolio includes Arrestin-EA cell lines, plasmids for expressing GPCRs and screening reagents for one step, homogeneous chemiluminescent detection.